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Abstract
Background: Multimorbidity is associated with higher healthcare utilization; however, data exploring its association
with readmission are scarce. We aimed to investigate which most important patterns of multimorbidity are
associated with 30-day readmission.
Methods: We used a multinational retrospective cohort of 126,828 medical inpatients with multimorbidity defined as
≥2 chronic diseases. The primary and secondary outcomes were 30-day potentially avoidable readmission (PAR) and
30-day all-cause readmission (ACR), respectively. Only chronic diseases were included in the analyses. We presented the
OR for readmission according to the number of diseases or body systems involved, and the combinations of diseases
categories with the highest OR for readmission.
Results: Multimorbidity severity, assessed as number of chronic diseases or body systems involved, was strongly
associated with PAR, and to a lesser extend with ACR. The strength of association steadily and linearly increased with
each additional disease or body system involved. Patients with four body systems involved or nine diseases already
had a more than doubled odds for PAR (OR 2.35, 95%CI 2.15–2.57, and OR 2.25, 95%CI 2.05–2.48, respectively). The
combinations of diseases categories that were most strongly associated with PAR and ACR were chronic kidney
disease with liver disease or chronic ulcer of skin, and hematological malignancy with esophageal disorders or mood
disorders, respectively.
Conclusions: Readmission was associated with the number of chronic diseases or body systems involved and with
specific combinations of diseases categories. The number of body systems involved may be a particularly interesting
measure of the risk for readmission in multimorbid patients.
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Background
Multimorbidity, most often defined as the co-occurrence
of two or more chronic diseases, is very frequent and af-
fects 50 to 99% of hospitalized patients in Western
countries [1–3]. Multimorbidity is strongly associated
with age, and we may expect its prevalence to further in-
crease in the coming years notably because of the rising
life expectancy [4]. Hospital readmission within 30 days
of discharge after an acute medical hospitalization is also
frequent, affecting about 20% of the patients [5, 6]. Both
multimorbidity and readmission have been associated
with higher healthcare expenditures [3, 5–9].
A few studies have described an association between
multimorbidity and readmission, but none looked at the
potentially avoidable readmissions (PAR) specifically [7,
10, 11]. Furthermore, those studies measured multimor-
bidity mostly as a count of diseases, but the lack of stand-
ard to define which diseases should be included in this
assessment limits generalizability of such analyses [12, 13].
Using validated indices or objective tools to categorize the
diseases, such as the Chronic Condition Indicator (CCI)
and the Clinical Classification Software (CCS) developed
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by the Healthcare Cost and Utilization Project, may im-
prove comparability between studies [12–15].
Recently, growing interest has developed to assess
non-random combinations of diseases among multimor-
bid patients [2, 3, 16–23]. However, little is known about
how readmission is associated with such combinations
of diseases, as well as with other measures of multimor-
bidity, such as the body systems involved. Furthermore,
multimorbidity is a complex concept, with possible in-
teractions between the different diseases leading to more
or less than multiplicative effects on the risk for re-
admission, but this has never been assessed.
Using standardized tools to define chronic diseases
and to classify them into clinically meaningful categor-
ies, the main objective of this study was to identify com-
binations of comorbidities associated with 30-day all-
cause readmissions (ACR), and more specifically with
30-day PAR, in a large multinational retrospective co-
hort of multimorbid medical inpatients, to quantify this
association, and to assess potential multiplicative effects
of the diseases on the risk for readmission. The second-
ary aim was to quantify the association between read-
missions and the number of chronic diseases and body
systems involved.
Methods
Study design and population
We used a retrospective cohort including all multimor-
bid patients discharged home or to a nursing home from
the medical inpatient wards of 11 large public hospitals
(all but one academic) of three countries: the USA (7
hospitals), Switzerland (3 hospitals) and Israel (1 hos-
pital) during calendar years 2010 and 2011. We defined
multimorbidity as the presence of at least two chronic
diseases. To categorize International Classification of
Diseases (ICD) codes, we used the CCI and the CCS de-
veloped by the Healthcare Cost and Utilization Project,
a Federal-State-Industry partnership sponsored by the
Agency for Healthcare Research and Quality (AHRQ)
[14, 15]. We included only chronic diseases according to
the CCI and classified them into the 18 body system cat-
egories of the CCI (listed in Additional file 1) and into
285 exclusive diseases categories according to the CCS.
For clinical relevance, we further merged some CCS cat-
egories and excluded ICD codes relating to risk factors,
complications of diseases, symptoms or screening strat-
egies (details in Additional file 1). All CCS categories
(with categories numbers) found in the patients are
listed in the Additional file 1. Reporting is in accordance
with the STrengthening the Reporting of OBservational
studies in Epidemiology (STROBE) statement [24]. All
data were identified using electronic medical records.
The dataset is not publically available, but it is available
from the corresponding author on reasonable request
(caroleelodie.aubert@insel.ch).
Outcomes
Our primary outcome was PAR to any inpatient ward of
the same hospital within 30 days following hospital dis-
charge. PAR was defined by the SQLape algorithm, as
previously described [25, 26]. Briefly, this algorithm clas-
sifies a readmission as unavoidable if it was foreseeable,
for example for planned oncologic treatment, or if it in-
volves a new body system not affected during the index
admission. Conversely, treatment complications are clas-
sified as avoidable. Our secondary outcome was ACR to
any inpatient ward of the same hospital. To avoid re-
cording outpatient visits, we included only stays of at
least 24 h.
Statistical analyses
We presented baseline characteristics as median with
interquartile range (IQR) for continuous variables and as
numbers with frequencies for categorical variables. We
performed a mixed-effects logistic univariable regression
with a random intercept for center to account for correl-
ation of the outcome data within the treating centers
and presented the results as odds ratio (OR) with 95%
confidence interval (CI) for PAR and ACR. We included
only chronic diseases for all analyses. We considered fol-
lowing predictor variables in three distinct analyses: 1)
count of diseases (2 to ≥10, reference = 2 diseases, as we
included only patients with multimorbidity); 2) number
of body system categories (1 to ≥7, reference = 1 body
system category); 3) combinations of two diseases cat-
egories. For the latter, we presented the 20 combinations
with the highest OR, comparing patients with to those
without the combination, and assessed interactions be-
tween the diseases categories of each combination using
the glmer function of the lme4 package in R, which im-
plements generalized mixed models. We presented the
results as either no significant interaction (0), more than
multiplicative effect (+) or less than multiplicative effect
(−). A more than multiplicative effect means that the
two diseases categories in combination increased the
odds for readmission more than just multiplying the
odds for readmission of each respective disease category
on its own. We performed all analyses with STATA 15.1
(StataCorp LP, College Station, TX, USA) or R version
3.4.4 (R Project for Statistical Computing).
Results
From the 147,806 discharged patients available in the co-
hort, 126,828 (85.8%) were identified as multimorbid and
included in the analysis, among which 12,203 (9.6%) had a
PAR (Additional file 1: Figure S1) and 19,749 (15.6%)
an ACR. Table 1 presents the baseline characteristics in
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relation to PAR. Median age was 64 years (IQR 52, 76)
and median length of stay 5 days (IQR 3, 8). Median num-
ber of diseases was 6 (IQR 4, 9) in patients with PAR and
5 [3, 7] in those without.
Number of diseases and odds for readmission
The OR for readmission progressively and linearly in-
creased with the number of diseases to up to 2.55
(95%CI 2.35–2.76) for PAR and 1.52 (95%CI 1.43–1.62)
for ACR in patients with ten or more diseases, compared
to two diseases (Fig. 1). The odds for PAR already more
than doubled in the presence of nine diseases (OR 2.25,
95%CI 2.05–2.48).
Number of body system categories and odds for
readmission
The OR for readmission progressively and linearly in-
creased with the number of body system categories to
up to 3.24 (95%CI 2.95–3.57) for PAR and 1.80 (95%CI
1.68–1.93) for ACR in patients with seven or more body
systems involved, compared to one body system involved
(Fig. 2). The odds for PAR already more than doubled in
the presence of four body systems involved (OR 2.35,
95%CI 2.15–2.57).
Combinations of diseases categories and odds for PAR
Table 2 presents the 20 combinations of diseases categor-
ies with the highest OR for PAR and the interactions be-
tween the diseases categories. The odds increased by 74 to
136%. Among those 20 combinations, urogenital diseases,
including chronic kidney disease, were most frequent,
while chronic ulcer of skin was found in one fifth of the
combinations. The highest OR (2.36, 95%CI 2.05–2.71)
was found for chronic kidney disease combined with liver
disease, followed by chronic kidney disease combined with
chronic ulcer of skin (OR 2.18, 95% CI 1.95–2.45). The
odds for PAR doubled for chronic heart disease combined
with other diseases of kidney and ureters, as well as for
chronic kidney disease combined with substance-related
disorders or with other diseases of kidney and ureters.
Three combinations of diseases categories (chronic kidney
disease with substance-related disorders; paralysis with
chronic ulcer of skin; esophageal disorders with liver dis-
ease) had a more than multiplicative effect on the odds for
PAR, and four combinations (chronic kidney disease with
other nutritional, endocrine or metabolic disorders;
chronic kidney disease with nephritis, nephrosis, renal
sclerosis; chronic kidney disease with chronic obstructive
pulmonary disease and bronchiectasis; chronic kidney
Table 1 Baseline characteristics
Characteristics Whole cohort (N = 126,828) With PAR (N = 12,203) Without PAR (N = 114,625)
Age, years 64 (52, 76) 63 (51, 75) 62 (52, 76)
Men 65,631 (51.7) 6481 (53.1) 59,150 (51.6)
Country
Israel 10,020 (7.9) 1299 (10.6) 8721 (7.6)
Switzerland 33,871 (26.7) 1948 (16.0) 31,923 (27.8)
United States 82,937 (65.4) 8956 (73.4) 73,981 (64.5)
Description of Morbidity
Number of chronic diseases 5 (3, 8) 6 (4, 9) 5 (3, 7)
Most frequent chronic diseases (prevalence > 10%)
Chronic heart disease 60,298 (47.5) 6159 (50.5) 54,139 (47.2)
Chronic kidney disease 22,210 (17.5) 3213 (26.3) 18,997 (16.6)
Mood disorders 18,932 (14.9) 2068 (16.9) 16,864 (14.7)
Arthropathy and arthritis 18,348 (14.5) 1722 (14.11) 16,626 (14.5)
Solid malignancy 18,045 (14.2) 2274 (18.6) 15,771 (13.8)
Esophageal disorders 17,864 (14.1) 2014 (16.5) 15,850 (13.8)
Other nervous system disorders 16,349 (12.9) 1952 (16.0) 14,397 (12.6)
Chronic obstructive pulmonary disease and bronchiectasis 14,696 (11.6) 1902 (15.6) 12,793 (11.2)
Thyroid disorders 14,640 (11.5) 1564 (12.8) 13,076 (11.4)
Substance-related disorders 12,863 (10.1) 1204 (9.9) 11,659 (10.2)
Hospitalization characteristics
Length of stay, days 5 (3, 8) 5 (3, 9) 4 (3, 8)
Number of admissions in the past year 0 (0, 2) 2 (0, 4) 0 (0, 2)
Data are N (%) or median with interquartile range
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disease with pulmonary heart disease) had a less than
multiplicative effect on the odds for PAR.
Combinations of diseases categories and odds for ACR
Table 3 displays the 20 combinations of diseases categor-
ies with the highest OR for ACR and the interactions be-
tween the diseases categories. The odds increased by 63
to 213%. A hematological malignancy was found among
the seven combinations with the highest OR, with a
maximal OR when combined with esophageal disorders
(OR 3.13, 95% CI 2.79–3.52). Chronic kidney disease
was the most frequent disease found in the following 13
combinations with the highest OR. In terms of inter-
action effect between the diseases categories, five combi-
nations had a less than multiplicative effect, and three
combinations had a more than multiplicative effect on
the odds for ACR.
Fig. 2 Odds ratios with 95% confidence intervals for a) potentially avoidable readmission and b) all-cause readmission according to the number
of body systems involved. Abbreviations: #, number of body systems; CI, confidence interval; N, number of patients; OR, odds ratio
Fig. 1 Odds ratios with 95% confidence intervals for a) potentially avoidable readmission and b) all-cause readmission according to the number
of chronic diseases. The reference is the presence of two chronic diseases, as we included only patients with multimorbidity. Abbreviations: #,
number of chronic diseases; CI, confidence interval; N, number of patients; OR, odds ratio
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Discussion
In this large multinational retrospective cohort of multi-
morbid medical inpatients, we found a strong and linear
association of 30-day PAR with the number of body sys-
tems involved, and to a lesser extend with the number
of chronic diseases. Having four body systems involved
or nine chronic diseases already more than doubled the
risk for PAR. The number of body systems may there-
fore be an interesting measure of the risk for readmis-
sion in multimorbid patients. The combinations of
diseases categories with the strongest association with
30-day PAR included chronic kidney disease with liver
disease or with chronic ulcer of skin, and chronic heart
disease with other diseases of kidney and ureters. For
ACR, the strongest associations were found for a
hematological malignancy combined with esophageal
disorders, with mood disorders or with diseases of white
blood cells.
Consistent with our findings, a few studies had de-
scribed a positive association between multimorbidity
and readmission in medical patients or Medicare benefi-
ciaries, but none had assessed specific patterns of multi-
morbidity [7, 10, 11]. Furthermore, in this study, unlike
previous authors, we separately assessed the outcomes
of PAR and ACR. This distinction allowed us to un-
cover two relevant points. First, greater multimorbid-
ity and similar combinations of diseases categories
were more strongly associated with PAR than with
ACR. Second, the combinations with the strongest as-
sociation with PAR or with ACR included different
categories of diseases.
While a hematological or a solid malignancy were fre-
quent among the 20 combinations with the highest odds
for ACR, we found neither a hematological nor a solid
malignancy among the combinations with the highest
odds for PAR. This suggests that hospitalizations related
to malignancy were for planned oncologic therapy rather
than for treatment complications that would have ap-
peared in relationship with PAR also, and not only with
ACR. In contrast, combinations with the highest odds
for PAR most often included chronic kidney disease.
Whereas repeated hospitalizations for planned oncologic
treatment are unavoidable, we may nonetheless influence
the rate of hospitalization related to diseases affecting
the urogenital tract. Describing which combinations of
diseases categories are associated with higher odds for
Table 2 Twenty combinations of diseases categories with the highest odds ratio for potentially avoidable readmission, in comparison
with patients without the combination, and the interactions between the diseases categories
Chronic disease 1 Chronic disease 2 OR (95% CI) Interaction
Chronic kidney disease Liver disease 2.36 (2.05;2.71) 0
Chronic kidney disease Chronic ulcer of skin 2.18 (1.95;2.45) 0
Chronic heart disease Other diseases of kidney and ureters 2.02 (1.75;2.34) 0
Chronic kidney disease Substance-related disorders 2.00 (1.73;2.32) +
Chronic kidney disease Other diseases of kidney and ureters 1.99 (1.76;2.26) 0
Chronic kidney disease Other nutritional, endocrine or metabolic disorders 1.93 (1.63;2.27) –
Chronic kidney disease Asthma 1.90 (1.64;2.19) 0
Chronic ulcer of skin Liver disease 1.89 (1.60;2.23) 0
Chronic kidney disease Epilepsy; convulsions 1.87 (1.56;2.24) 0
Chronic kidney disease Nephritis, nephrosis, renal sclerosis 1.87 (1.66;2.09) –
Paralysis Chronic ulcer of skin 1.86 (1.55;2.22) +
Chronic kidney disease Mood disorders 1.83 (1.65;2.02) 0
Solid malignancy Asthma 1.82 (1.51;2.18) 0
Chronic kidney disease Chronic obstructive pulmonary disease and bronchiectasis 1.78 (1.62;1.96) –
Peripheral and visceral atherosclerosis Chronic ulcer of skin 1.78 (1.45;2.17) 0
Esophageal disorders Liver disease 1.76 (1.54;2.01) +
Chronic heart disease Nephritis, nephrosis, renal sclerosis 1.76 (1.54;2.00) 0
Chronic kidney disease Pulmonary heart disease 1.74 (1.56;1.94) –
Other nervous system disorders Pulmonary heart disease 1.74 (1.47;2.06) 0
Mood disorders Liver disease 1.74 (1.47;2.05) 0
Abbreviations: CI confidence interval, OR odds ratio
The signs “+” and “-” represent diseases categories with a significant more than multiplicative effect and less than multiplicative effect on the odds for
readmission, respectively. A more than multiplicative effect means that the two diseases categories in combination increase the odds for readmission more than
just by multiplying the odds for readmission of each disease category separately. The sign “0” means that the interaction is not significant
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PAR specifically, rather than for ACR, may therefore
help to identify situations of vulnerability that should be
detected early in order to focus those efficient preventive
interventions on higher-risk patients.
The high frequency of chronic kidney disease
among the combinations with the strongest associ-
ation with PAR suggests that patients with chronic
kidney disease are particularly affected by adverse
consequences of multimorbidity, especially higher
healthcare resource utilization. This might be due to
the high number of complications related to chronic
kidney disease, such as bone disease, coagulation dis-
turbances, anemia or cardiovascular diseases. Interest-
ingly, when looking at combinations most strongly
associated with ACR after excluding hematological
and solid malignancy, eight of the nine combinations
were also found among the 20 top combinations asso-
ciated with PAR, and included mostly chronic kidney
disease. This suggests that these associations found
for AR were related to PAR rather than to unavoid-
able readmissions, and underlines again the target
group for preventive interventions represented by pa-
tients with chronic kidney disease.
We found higher OR for ACR than for PAR. At a first
sight, this may seem inconsistent with the stronger rela-
tionship with PAR when assessing multimorbidity as a
count of diseases or of body systems involved. However,
when comparing the results for the same combinations
of diseases categories, the OR for PAR was higher than
for ACR. We can thus explain the higher OR for ACR
than for PAR by the fact that the seven top combina-
tions of diseases with the highest OR for ACR increased
the odds for unavoidable rather than for avoidable re-
admission, which are both included in the composite
outcome of ACR. While many studies described frequent
combinations of diseases, we found no data assessing
their association with readmission that could be com-
pared with our results [2, 3, 16–23].
Previous analyses showed that the burden of multi-
morbidity increased with each additional disease [7, 8].
In Medicare beneficiaries, the rate of readmission was
indeed about 12% in the presence of 0 or 1 chronic con-
dition, and 30% in the presence of six or more chronic
conditions, respectively [7]. However, this analysis was
restricted to 15 chronic conditions selected from the
CMS Chronic Conditions Warehouse (CWS) and to
Table 3 Twenty combinations of diseases categories with the highest odds ratio for all-cause readmission, in comparison with
patients without the combination, and the interactions between the diseases categories
Chronic disease 1 Chronic disease 2 OR (95% CI) Interaction
Hematological malignancy Esophageal disorders 3.13 (2.79;3.52) 0
Hematological malignancy Mood disorders 2.90 (2.57;3.28) 0
Hematological malignancy Diseases of white blood cells 2.82 (2.58;3.09) –
Hematological malignancy Thyroid disorders 2.48 (2.14;2.88) 0
Hematological malignancy Other nervous system disorders 2.40 (2.12;2.71) –
Hematological malignancy Arthropathy and arthritis 2.23 (1.90;2.61) 0
Hematological malignancy Chronic heart disease 2.18 (1.99;2.39) –
Chronic kidney disease Liver disease 2.03 (1.79;2.32) 0
Solid malignancy Asthma 1.84 (1.58;2.15) 0
Chronic heart disease Other diseases of kidney and ureters 1.84 (1.62;2.10) 0
Chronic kidney disease Chronic ulcer of skin 1.84 (1.66;2.04) 0
Solid malignancy Substance-related disorders 1.812(1.58;2.08) 0
Hematological malignancy Chronic kidney disease 1.80 (1.54;2.10) –
Liver disease Chronic ulcer of skin 1.78(1.53;2.07) 0
Chronic kidney disease Other diseases of kidney and ureters 1.73 (1.55;1.93) 0
Esophageal disorders Liver disease 1.72 (1.54;1.92) +
Chronic kidney disease Substance-related disorders 1.70 (1.49;1.93) +
Solid malignancy Diseases of white blood cells 1.69 (1.50;1.91) –
Chronic kidney disease Diseases of white blood cells 1.67 (1.41;1.99) 0
Chronic kidney disease Epilepsy; convulsions 1.63 (1.38;1.93) +
Abbreviations: CI confidence interval, OR odds ratio
The signs “+” and “-” represent diseases categories with a significant more than multiplicative effect and less than multiplicative effect on the odds for
readmission, respectively. A more than multiplicative effect means that the two diseases categories in combination increase the odds for readmission more than
just by multiplying the odds for readmission of each disease category separately. The sign “0” means that the interaction is not significant
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Medicare patients only, and categorized broadly the
numbers of chronic conditions (0–1, 2–3, 4–5, 6 or
more), while we did not limit our analysis to Medicare
patients. Until now, little was known about the cutoffs at
which the odds for readmission doubles. Furthermore,
we lacked data on how the different diseases may inter-
act together to influence the odds for readmission, i.e.
whether the odds associated with each disease just
multiply, or if sometimes more or less than multiplica-
tive effects may exist. We therefore assessed interactions
between combinations of diseases categories to uncover
potentially more complex effects on the odds for re-
admission. Among the 20 combinations of diseases cat-
egories with the highest OR for PAR or ACR, we found
that more than one third of the diseases significantly
interacted together, most often negatively, corresponding
to a less than multiplicative effect on the odds for re-
admission, and less often positively, corresponding to a
more than multiplicative effect on the odds.
These various patterns of interactions, as well as the
stronger association with the number of body system in-
volved than with the number of diseases, support the
fact that multimorbidity is a complex concept and that
measuring it simply as a count of diseases may not be
accurate enough and mask important information on
the exact risk associated with particular combinations of
diseases [12, 13]. A refined and standardized definition
of multimorbidity taking this consideration into account
might be useful.
Strengths and limitations
Our study presents some limitations. First, we included
only readmissions to the same medical center. There-
fore, we cannot exclude to have missed some readmis-
sions to other medical hospitals. Second, as we wanted
to focus on multimorbidity of medical patients, our re-
sults may not be generalizable to other patients’ popula-
tion such as surgical patients. Third, although we could
assess a broad number of diseases using ICD codes,
some diagnoses may not have been coded, so that we
cannot exclude some underreporting. Finally, the restric-
tion of our analysis to chronic diseases may have pre-
vented comparison with other studies that also included
risk factors and complications of diseases.
This study has a number of strengths also. First, this is
the first such study using a large, multinational and multi-
center sample of medical inpatients, increasing results’
generalizability. Second, we included a large number of
diseases and assessed multimorbidity with standardized
classification tools that allow reproducibility [14, 15].
Third, we studied the association of readmission with
multimorbidity in several ways, using the total count of
diseases, the number of body systems involved, as well as
combinations of diseases categories and the interactions
between the diseases categories. Finally, unlike previous
studies, we distinguished PAR and ACR, which allowed
uncover unknown and clinically relevant differences.
Conclusions
In a large cohort of multimorbid medical inpatients, we
found that the odds for 30-day PAR and ACR increased
progressively and linearly with the number of body sys-
tems involved and with the number of chronic diseases.
Chronic kidney disease was almost constantly present in
the combinations of diseases categories with the highest
OR for PAR. The odds for PAR more than doubled in
the presence of four body systems involved. The number
of body systems involved may represent an interesting,
simple and useful way to assess the risk for readmission
in multimorbid medical patients. The identification of
combination of diseases with a higher risk for PAR spe-
cifically is of particular relevance because it may help to
target preventive interventions to high-risk patients
most likely to benefit.
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